Rocket Pharmaceuticals (RCKT) Interest Expenses (2014 - 2026)

Rocket Pharmaceuticals has disclosed Interest Expenses across 12 years of filings, most recently posting $473000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $473000.0, changed 0.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (changed 0.26% YoY), and the FY2025 annual result was $1.9 million, changed 0.27% from the prior year.
• Interest Expenses came in at $473000.0 for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $473000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $473000.0 in Q4 2024 to a low of $464000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $471000.0 (2024), against an average of $469764.7.
• Peak annual rise in Interest Expenses reached 85.26% in 2022, while the deepest fall reached 73.16% in 2022.
• Rocket Pharmaceuticals' Interest Expenses stood at $467000.0 in 2022, then climbed by 0.64% to $470000.0 in 2023, then advanced by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025, then changed by 0.0% to $473000.0 in 2026.
• The last three Interest Expenses figures came in at $473000.0 (Q1 2026), $473000.0 (Q4 2025), and $473000.0 (Q3 2025), per Business Quant data.